The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
Authors:
Open Access
- 5 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0180624
Abstract
Hematopoietic recovery is considered to be associated with the number of multipotent hematopoietic stem cells in the bone marrow, as observed in functional assays involving stem cell transplantation. However, there is little evidence related to hematopoietic recovery in non-transplantation settings, which is accomplished by endogenous hematopoietic cells. A recent study suggested that progenitors are the main contributors during this steady-state hematopoiesis, which differs from exogenous transplantation. We hypothesized that endogenous progenitor support post-chemotherapy hematopoietic recovery. To investigate the potential impact of these progenitor cell percentage on hematopoietic recovery, we retrospectively analyzed the percentage of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells (P cells) and hematopoietic recovery in 223 newly diagnosed acute myeloid leukemia patients during two courses of consolidation chemotherapy after complete remission. We found that a lower P cell percentage was significantly associated with prolonged neutropenia recovery time after the first and second courses of consolidation chemotherapy (p = 0.001; p = 0.045, respectively). We also observed similar results with regard to platelet recovery time after the first course of consolidation chemotherapy (p = 0.000). Univariate analysis showed that P cell percentage and consolidation chemotherapy regimens, and not gender, age, induction chemotherapy regimens, infection grade, WHO classification and NCCN risk category, were associated with neutrophil recovery after chemotherapy. Multivariate analysis demonstrated that P cell percentage is an independent factor affecting neutrophil recovery capacity for both the first and second courses (p = 0.008; p = 0.032, respectively). Our results indicate that CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells before each course of chemotherapy is independently associated with chemotherapy-related hematopoietic reconstitution capacity. These findings may help modify future chemotherapy regimens based on progenitor cell percentages.Keywords
Funding Information
- State Key Program of the National Natural Science of China (81430004)
- Foundation for Innovative Research Groups of the Natural Science Foundation of China (81421002)
- National Natural Science Foundation of China (CN) (81400136)
- National Natural Science Foundation of China (81570147)
- National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2014BAI09B12)
This publication has 21 references indexed in Scilit:
- Dynamic niches in the origination and differentiation of haematopoietic stem cellsNature Reviews Molecular Cell Biology, 2011
- MicroRNA miR-125a controls hematopoietic stem cell numberProceedings of the National Academy of Sciences, 2010
- Stem Cells and Early Lineage DevelopmentCell, 2008
- Limiting Factors in Murine Hematopoietic Stem Cell AssaysCell Stem Cell, 2007
- Mammary stem cell number as a determinate of breast cancer riskBreast Cancer Research, 2007
- Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell DosesTransplantation and Cellular Therapy, 2007
- Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesisBreast Cancer Research, 2007
- The hematopoietic stem compartment consists of a limited number of discrete stem cell subsetsBlood, 2006
- Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic PotentialCell, 2005
- Chemotherapy and Bone Marrow Reserve: Lessons Learned from Autologous Stem Cell TransplantationCancer Biotherapy and Radiopharmaceuticals, 2002